View Financial HealthApimeds Pharmaceuticals US 配当と自社株買い配当金 基準チェック /06Apimeds Pharmaceuticals US配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 16Apimeds Pharmaceuticals US, Inc. announced delayed 10-Q filingOn 05/15/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 23Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual ReportApimeds Pharmaceuticals US, Inc. (the "Company") announced that on April 17, 2026, it received a notice of non-compliance (the "Notice") with the continued listing standards set in Section 1007 of the Company Guide of NYSE American LLC ("NYSE American"). The Notice was issued in connection with the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2025 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). As disclosed in a Form 12b-25 filed with the SEC on March 31, 2026, the Company was unable to file the Form 10-K within the prescribed time period without unreasonable effort or expense due to (i) the continued preparation and finalization of the Company's financial statements for the fourth quarter and fiscal year ended December 31, 2025, and (ii) the additional time required for the Company's independent registered public accounting firm to complete its audit procedures. The Company expects to file the Form 10-K by April 30, 2026. While the Company is making substantial progress toward completion, there can be no assurance that the Form 10-K will be filed by such date. The Company's common stock will continue to be listed on the NYSE American under the ticker symbol "APUS" while it attempts to regain compliance with the listing standard noted, but will have an added designation of ".LF" to signify the Company's late filing status, which will remain in place until the Company regains compliance with the applicable listing standard. The April 2, 2026, trading halt on the Company's common stock remains in effect and is not currently affected by the receipt of the Notice. NYSE Regulation, which monitors whether an issuer listed on the NYSE American has timely filed its annual and interim reports with the SEC, has informed the Company that during the period ending on October 15, 2026 (the "Initial Cure Period"), the NYSE American will monitor the Company and the status of the Form 10-K and any subsequent annual or quarterly report that the Company fails to file by the applicable due date ("Subsequent Reports") until the Form 10-K has been filed with the SEC. If the Company fails to file the Form 10-K and any Subsequent Reports within the Initial Cure Period, the NYSE American may, in the NYSE American's sole discretion, allow the Company's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Company's specific circumstances. NYSE Regulation has informed the Company that if the NYSE American determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. The NYSE American may, in its sole discretion, decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE American believes, in the NYSE American's sole discretion, that continued listing and trading of the Company's securities on the NYSE American is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company is making this announcement in compliance with Section 1007 of the Company Guide, which requires prompt disclosure of receipt of the Notice. The Notice also requires the Company to speak to the NYSE American within five days of the receipt of the Notice, which the Company will do.お知らせ • Apr 01Apimeds Pharmaceuticals US, Inc. announced delayed annual 10-K filingOn 03/31/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Mar 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Minguk Ji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$0 This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$0 market cap).お知らせ • Mar 25+ 2 more updatesApimeds Pharmaceuticals Us, Inc. Removes Erick Frim as Chief Financial OfficerApimeds Pharmaceuticals US, Inc. removed Erick Frim as chief financial officer of the Company.お知らせ • Feb 12Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox)Apimeds Pharmaceuticals US, Inc. and Lokahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S. LT-100 is pure honeybee venom, with a long history of clinical investigation. The product was originally developed and approved in South Korea, where it was approved for marketing in South Korea by the Korean Food and Drug Administration (KFDA; now the Ministry of Food and Drug Safety [MFDS). Apimeds and Lokahi Therapeutics are now advancing the program in the U. S. by integrating its historical data with rigorous development standards.お知らせ • Jan 03Apimeds Pharmaceuticals Us, Inc. Announces Removal of Erik Emerson from Board of Directors, Effective December 30, 2025Apimeds Pharmaceuticals US, Inc. announced that on December 30, 2025, the stockholders, acting by written consent, removed Erik Emerson from the Company's board of directors, effective as of that date. The removal was effected by the affirmative vote of stockholders holding a majority of the outstanding shares of common stock of the Company's voting power entitled to vote generally in the election of directors, and was taken with or without cause, in accordance with the Company's organizational documents and applicable law. The following remain members of the Company's board of directors: Elona Kogan, Jakap Koo, Carol O'Donnell, Dr. Bennett Weintraub, PhD.お知らせ • Dec 11Apimeds Pharmaceuticals Us, Inc. Announces Board ResignationsApimeds Pharmaceuticals US, Inc. announced that on December 5, 2025, Dr. Vin Menon, a Director of Apimeds Pharmaceuticals US, Inc., and Amir A. Dossal, an Independent Director of the Company, resigned from their positions on the Company's Board of Directors. The resignations were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.お知らせ • Dec 10Apimeds Pharmaceuticals US, Inc. announced that it has received $100 million in fundingOn December 10, 2025, Apimeds Pharmaceuticals US, Inc. closed the transaction. The company raised $100,000,000 in the transaction.決済の安定と成長配当データの取得安定した配当: APUSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: APUSの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Apimeds Pharmaceuticals US 配当利回り対市場APUS 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (APUS)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (APUS) (最長3年)n/a注目すべき配当: APUSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: APUSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: APUSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: APUSが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 13:27終値2026/05/22 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Apimeds Pharmaceuticals US, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 16Apimeds Pharmaceuticals US, Inc. announced delayed 10-Q filingOn 05/15/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 23Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual ReportApimeds Pharmaceuticals US, Inc. (the "Company") announced that on April 17, 2026, it received a notice of non-compliance (the "Notice") with the continued listing standards set in Section 1007 of the Company Guide of NYSE American LLC ("NYSE American"). The Notice was issued in connection with the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2025 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). As disclosed in a Form 12b-25 filed with the SEC on March 31, 2026, the Company was unable to file the Form 10-K within the prescribed time period without unreasonable effort or expense due to (i) the continued preparation and finalization of the Company's financial statements for the fourth quarter and fiscal year ended December 31, 2025, and (ii) the additional time required for the Company's independent registered public accounting firm to complete its audit procedures. The Company expects to file the Form 10-K by April 30, 2026. While the Company is making substantial progress toward completion, there can be no assurance that the Form 10-K will be filed by such date. The Company's common stock will continue to be listed on the NYSE American under the ticker symbol "APUS" while it attempts to regain compliance with the listing standard noted, but will have an added designation of ".LF" to signify the Company's late filing status, which will remain in place until the Company regains compliance with the applicable listing standard. The April 2, 2026, trading halt on the Company's common stock remains in effect and is not currently affected by the receipt of the Notice. NYSE Regulation, which monitors whether an issuer listed on the NYSE American has timely filed its annual and interim reports with the SEC, has informed the Company that during the period ending on October 15, 2026 (the "Initial Cure Period"), the NYSE American will monitor the Company and the status of the Form 10-K and any subsequent annual or quarterly report that the Company fails to file by the applicable due date ("Subsequent Reports") until the Form 10-K has been filed with the SEC. If the Company fails to file the Form 10-K and any Subsequent Reports within the Initial Cure Period, the NYSE American may, in the NYSE American's sole discretion, allow the Company's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Company's specific circumstances. NYSE Regulation has informed the Company that if the NYSE American determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. The NYSE American may, in its sole discretion, decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE American believes, in the NYSE American's sole discretion, that continued listing and trading of the Company's securities on the NYSE American is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company is making this announcement in compliance with Section 1007 of the Company Guide, which requires prompt disclosure of receipt of the Notice. The Notice also requires the Company to speak to the NYSE American within five days of the receipt of the Notice, which the Company will do.
お知らせ • Apr 01Apimeds Pharmaceuticals US, Inc. announced delayed annual 10-K filingOn 03/31/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Mar 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Minguk Ji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$0 This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$0 market cap).
お知らせ • Mar 25+ 2 more updatesApimeds Pharmaceuticals Us, Inc. Removes Erick Frim as Chief Financial OfficerApimeds Pharmaceuticals US, Inc. removed Erick Frim as chief financial officer of the Company.
お知らせ • Feb 12Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox)Apimeds Pharmaceuticals US, Inc. and Lokahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S. LT-100 is pure honeybee venom, with a long history of clinical investigation. The product was originally developed and approved in South Korea, where it was approved for marketing in South Korea by the Korean Food and Drug Administration (KFDA; now the Ministry of Food and Drug Safety [MFDS). Apimeds and Lokahi Therapeutics are now advancing the program in the U. S. by integrating its historical data with rigorous development standards.
お知らせ • Jan 03Apimeds Pharmaceuticals Us, Inc. Announces Removal of Erik Emerson from Board of Directors, Effective December 30, 2025Apimeds Pharmaceuticals US, Inc. announced that on December 30, 2025, the stockholders, acting by written consent, removed Erik Emerson from the Company's board of directors, effective as of that date. The removal was effected by the affirmative vote of stockholders holding a majority of the outstanding shares of common stock of the Company's voting power entitled to vote generally in the election of directors, and was taken with or without cause, in accordance with the Company's organizational documents and applicable law. The following remain members of the Company's board of directors: Elona Kogan, Jakap Koo, Carol O'Donnell, Dr. Bennett Weintraub, PhD.
お知らせ • Dec 11Apimeds Pharmaceuticals Us, Inc. Announces Board ResignationsApimeds Pharmaceuticals US, Inc. announced that on December 5, 2025, Dr. Vin Menon, a Director of Apimeds Pharmaceuticals US, Inc., and Amir A. Dossal, an Independent Director of the Company, resigned from their positions on the Company's Board of Directors. The resignations were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
お知らせ • Dec 10Apimeds Pharmaceuticals US, Inc. announced that it has received $100 million in fundingOn December 10, 2025, Apimeds Pharmaceuticals US, Inc. closed the transaction. The company raised $100,000,000 in the transaction.